Black Diamond Therapeutics Presents Promising BDTX-1535 Clin

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging ant

Related Keywords

United States , Arizona , Cambridge , Cambridgeshire , United Kingdom , Black Diamond , American , Patrick Wen , Nader Sanai , Mario Corso , American Society Of Clinical Oncology , Oncology At Dana Farber Cancer Institute , Ivy Brain Tumor Center Clinical , Nasdaq , Ivy Brain Tumor Center , Company Masterkey , International Conference On Molecular , Diamond Therapeutics Inc , Exchange Commission , Diamond Therapeutics , American Society , Clinical Oncology , Dana Farber Cancer Institute , Generation Covalent , Recurrent Glioblastoma , Dose Escalation Results , Molecular Targets , Trigger Trial , Recurrent High Grade Glioma , Private Securities Litigation Reform Act , Annual Report , United States Securities , Investor Relations ,